CLINICAL TRIALS PROFILE FOR CABOTEGRAVIR SODIUM
✉ Email this page to a colleague
All Clinical Trials for CABOTEGRAVIR SODIUM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02345707 ↗ | Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir | Completed | ViiV Healthcare | Phase 1 | 2015-03-01 | This study is a single-center, randomized, open-label, two cohorts, 3-way cross-over design in 36 subjects to assess the oral bioavailability of four new cabotegravir (CAB) sodium salt tablet formulations relative to the current CAB sodium salt formulation being used in the phase IIb studies under fasting conditions. All treatments will be administered as single 30 mg doses of CAB. Safety evaluations and serial PK samples will be collected during each treatment period. A follow-up visit will occur 10 - 14 days after the last dose of study drug. Treatment period doses will be separated by a 14 day washout. Participation in this study will be approximately 12 weeks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CABOTEGRAVIR SODIUM
Condition Name
Clinical Trial Locations for CABOTEGRAVIR SODIUM
Trials by Country
Clinical Trial Progress for CABOTEGRAVIR SODIUM
Clinical Trial Phase
Clinical Trial Sponsors for CABOTEGRAVIR SODIUM
Sponsor Name
